Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene
and is constitutively expressed on the surface of immune cells. As a receptor and immune …

Thalidomide, lenalidomide and pomalidomide are immunomodulatory drugs (IMiDs)
effective in the treatment of multiple myeloma, myelodysplastic syndrome (MDS) with …

Experimental evidence indicates that mesenchymal stromal cells (MSCs) may regulate
tumor microenvironment (TME). It is conceivable that the interaction with MSC can influence …

Accumulating evidence suggests that the tumor microenvironment (TME) is involved in
disease progression and drug resistance in B cell malignancies, by supporting tumor growth …

The DNA-PK holoenzyme is a fundamental element of the DNA damage response
machinery (DDR), which is responsible for cellular genomic stability. Consequently, and …

Aggressive B-cell lymphomas that are primary refractory to, or relapse after, frontline
chemoimmunotherapy have a low cure rate with conventional therapies. Although high-dose …

The multicenter, phase Ib CC‐122‐DLBCL‐001 dose‐expansion study (NCT02031419)
explored the cereblon E3 ligase modulator (CELMoD) agent avadomide (CC‐122) plus …

Thalidomide and its derivatives (lenalidomide, pomalidomide, avadomide, iberdomide
hydrochoride, CC-885 and CC-90009) form the family of immunomodulatory drugs (IMiDs) …

As a post-translational modification that has pivotal roles in protein degradation,
ubiquitination ensures that intracellular proteins act in a precise spatial and temporal …

There is a need for additional treatment options for patients with relapsed or refractory
diffuse large B‐cell lymphoma (DLBCL) who do not benefit from available therapies. We …